Neuburgh Advisers’s Intersect ENT, Inc XENT Stock Holding History

Neuburgh Advisers’s Portfolio XENT Stock Details XENT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q2	–	Sell	-2,822	Closed	-$111K	–	916
2018 Q1	$111K	Sell	2,822 -8,500	-75%	-$310K	﹤0.01%	775
2017 Q4	$367K	Sell	11,322 -5,678	-33%	-$170K	0.01%	506
2017 Q3	$530K	Sell	17,000 -2,108	-11%	-$62.4K	0.02%	381
2017 Q2	$534K	Sell	19,108 -6,392	-25%	-$145K	0.02%	381
2017 Q1	$437K	Hold	25,500	–	–	0.02%	378
2016 Q4	$309K	Buy	+25,500	New	+$330K	0.01%	398

Other funds holding XENT

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

HealthCor Management New York $109M AUM 10.64% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Neuburgh Advisers's XENT Position: Q2 2018 in Review

Neuburgh Advisers sold out of Intersect ENT, Inc (XENT) in Q2 2018, closing a stake of 2,822 shares — an estimated $111K sold.

Neuburgh Advisers first reported a position in XENT in Q4 2016 and held it in 6 quarters. The position peaked at $534K in Q2 2017. 160 funds tracked by Wall St. Rank hold XENT as of Q2 2018.

Neuburgh Advisers reported no remaining Intersect ENT, Inc position as of Q2 2018 after selling out during the quarter.
Neuburgh Advisers sold 2,822 Intersect ENT, Inc shares in Q2 2018, an estimated $111K.
Neuburgh Advisers first reported a position in Intersect ENT, Inc in Q4 2016 and held it in 6 quarters.
Neuburgh Advisers's Intersect ENT, Inc position peaked at $534K in Q2 2017.
160 funds tracked by Wall St. Rank held Intersect ENT, Inc as of Q2 2018.

Based on Neuburgh Advisers's 13F filing for Q2 2018, filed 10 Aug 2018.